ReviewHematology. American Society of Hematology. Education Program2018
New insights into the pathophysiology and development of novel therapies for sickle cell disease.
Review in Hematology. American Society of Hematology. Education Program, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Low bone mineral density and pain impact in adults with sickle cell disease.Blood advances · 2026Article
- Beyond IV push: alternative methods for management of acute pain in SCD.Hematology. American Society of Hematology. Education Program · 2024Review
- Concentration of voxelotor in sickle cell disease can be estimated using electrophoresis and high-performance liquid chromatography.American journal of clinical pathology · 2024Article
- A comparison of the mixed and sequential use of acetaminophen and dexketoprofen in painful vaso-occlusive crises.European journal of clinical pharmacology · 2024Article
- A novel composition of endogenous metabolic modulators improves red blood cell properties in sickle cell disease.EJHaem · 2024Article
- Review
- Catch bonds in sickle cell disease: Shear-enhanced adhesion of red blood cells to laminin.Biophysical journal · 2023Article
- Insights into Sickle Cell Disease through the Retinal Microvasculature: Adaptive Optics Scanning Light Ophthalmoscopy Correlates of Clinical OCT Angiography.Ophthalmology science · 2022Article
- Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases.Heliyon · 2022Review
- Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing.International journal of molecular sciences · 2021Review
- Characterization and statistical modeling of glycosylation changes in sickle cell disease.Blood advances · 2021Article
- Management of Sickle Cell Disease Complications Beyond Acute Chest Syndrome.Journal of blood medicine · 2021Review
- Irisin: A Promising Target for Ischemia-Reperfusion Injury Therapy.Oxidative medicine and cellular longevity · 2021Review
- Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease.Therapeutic advances in hematology · 2020Review
- Updated mechanisms underlying sickle cell disease-associated pain.Neuroscience letters · 2019Review
- Emerging disease-modifying therapies for sickle cell disease.Haematologica · 2019Review
- Omega 3 fatty acids - Potential modulators for oxidative stress and inflammation in the management of sickle cell disease.Jornal de pediatriaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Although the seminal event in sickle cell disease is the polymerization of abnormal hemoglobin, the downstream pathophysiology of vasoocclusion results from heterotypic interactions between the altered, adhesive sickle cell red blood cells, neutrophils, endothelium, and platelets. Ischemia reperfusion injury, hemolysis, and oxidant damage all contribute to heightened inflammation and activation of the hemostatic system. These various pathways are the focus of emerging treatments with potential to ameliorate disease manifestations. This review summarizes the considerable progress in development of these agents despite challenges in selection of study end points and complex pathophysiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.